CERo Therapeutics Holdings, Inc. CERO
$0.01
$0.004.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.16% | 14.02% | 36.31% | -24.80% | 9.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.18% | -5.11% | 116.26% | 10.46% | 5.50% |
| Operating Income | 29.18% | 5.11% | -116.26% | -10.46% | -5.50% |
| Income Before Tax | 81.01% | -15.28% | -775.79% | -14.86% | -121.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 81.01% | -15.28% | -775.79% | -14.86% | -121.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.01% | -15.28% | -775.79% | -14.86% | -121.23% |
| EBIT | 29.18% | 5.11% | -116.26% | -10.46% | -5.50% |
| EBITDA | 29.35% | 4.90% | -123.32% | -11.77% | -6.51% |
| EPS Basic | 98.87% | 99.36% | 93.13% | 94.66% | 3.26% |
| Normalized Basic EPS | 98.37% | 99.31% | 99.17% | 97.74% | -- |
| EPS Diluted | 98.87% | 99.36% | 93.13% | 94.66% | 3.26% |
| Normalized Diluted EPS | 98.37% | 99.31% | 99.17% | 97.74% | -- |
| Average Basic Shares Outstanding | 8,540.65% | 16,676.60% | 26,139.93% | 5,000.40% | -- |
| Average Diluted Shares Outstanding | 8,540.65% | 16,676.60% | 26,139.93% | 5,000.40% | 1,187.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |